Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage

Pediatric Blood and Cancer

Volumn 60, Issue 4, 2013, Pages 688-693

  Berry, Jesse L ^a   Jubran, Rima ^b   Kim, Jonathan W ^a,b   Wong, Kenneth ^b   Bababeygy, Simon R ^a   Almarzouki, Hashem ^b   Lee, Thomas C ^a,b   Murphree, A Linn ^b  

^a DOHENY EYE INSTITUTE   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

Chemoreduction; Chemotherapy; Intensity modulated radiation therapy; Retinoblastoma; Treatment outcomes

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IODINE 125; RUTHENIUM 106; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CRYOTHERAPY; DRUG RESPONSE; ENUCLEATION; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; INFANT; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RADIATION DOSE; RADIATION RESPONSE; RETINOBLASTOMA; RETROSPECTIVE STUDY; TUMOR RECURRENCE; VISUAL ACUITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMORADIOTHERAPY; CHILD, PRESCHOOL; ETOPOSIDE; HUMANS; INFANT; RADIOTHERAPY, INTENSITY-MODULATED; RETINAL NEOPLASMS; RETINOBLASTOMA; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; VINCRISTINE;

EID: 84873739203     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24303     Document Type: Article

References (44)

1. Ericson LA, Rosengren BH. Tests of intravitreous chemotherapy in retinoblastoma. Acta Ophthalmol (Copenh) 1962; 40: 121-122.
2. Pratt CB. Topical topic. Use of chemotherapy for retinoblastoma. Med Pediatr Oncol 1998; 31: 531-533.
3. White L. Chemotherapy for retinoblastoma: Where do we go from here? A review of published literature and meeting abstracts, including discussions during the Vth International Symposium on Retinoblastoma, October 1990. Ophthalmic Paediatr Genet 1991; 12: 115-130.
4. Murphree AL, Villablanca JG, Deegan WF III, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114: 1348-1356.
5. Gallie BL, Budning A, DeBoer G, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996; 114: 1321-1328.
6. Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996; 114: 1330-1338.
7. Shields CL, Mashayekhi A, Cater J, et al. Chemoreduction for retinoblastoma: Analysis of tumor control and risks for recurrence in 457 tumors. Trans Am Ophthalmol Soc 2004; 102: 35-44, discussion 44-35.
8. Shields JA, Shields CL, Meadows AT. Chemoreduction in the management of retinoblastoma. Am J Ophthalmol 2005; 140: 505-506.
9. Murphree AL. Intraocular retinoblastoma: The case for a new group classification. Ophthalmol Clin North Am 2005; 18: 41-53.
10. Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113: 2276-2280.
11. Shields CL, Shields JA. Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol 2006; 17: 228-234.
12. Cohen VM, Kingston J, Hungerford JL. The success of primary chemotherapy for group D heritable retinoblastoma. Br J Ophthalmol 2009; 93: 887-890.
13. Shin JY, Kim JH, Yu YS, et al. Eye-preserving therapy in retinoblastoma: Prolonged primary chemotherapy alone or combined with local therapy. Korean J Ophthalmol 2010; 24: 219-224.
14. Qian J, Xue K, Gao YJ, et al. Clinical therapeutic efficiency of chemoreduction and local therapy for children with retinoblastoma. Zhonghua Yan Ke Za Zhi 2010; 46: 312-316.
15. Abramson DH, Beaverson KL, Chang ST, et al. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol 2004; 122: 1316-1323.
16. Suzuki S, Yamane T, Mohri M, et al. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: The long-term prognosis. Ophthalmology 2011; 118: 2081-2087.
17. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152: 726-732.
18. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. Br Med J 2010; 340: c869.
19. Chan MP, Hungerford JL, Kingston JE, et al. Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: Rate of eye and vision preservation. Br J Ophthalmol 2009; 93: 891-894.
20. Peylan-Ramu N, Bin-Nun A, Skleir-Levy M, et al. Orbital growth retardation in retinoblastoma survivors: Work in progress. Med Pediatr Oncol 2001; 37: 465-470.
21. Imhof SM, Mourits MP, Hofman P, et al. Quantification of orbital and mid-facial growth retardation after megavoltage external beam irradiation in children with retinoblastoma. Ophthalmology 1996; 103: 263-268.
22. Fontanesi J, Parham DM, Pratt C, et al. Second malignant neoplasms in children with retinoblastoma: The St. Jude Children's Research Hospital experience. Ophthalmic Genet 1995; 16: 105-108.
23. Araki Y, Matsuyama Y, Kobayashi Y, et al. Secondary neoplasms after retinoblastoma treatment: Retrospective cohort study of 754 patients in Japan. Jpn J Clin Oncol 2011; 41: 373-379.
24. Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 1988; 95: 1583-1587.
25. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: An extended follow-up. J Clin Oncol 2005; 23: 2272-2279.
26. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: A possible age effect on radiation-related risk. Ophthalmology 1998; 105: 573-579, discussion 579-580.
27. Reisner ML, Viegas CM, Grazziotin RZ, et al. Retinoblastoma-comparative analysis of external radiotherapy techniques, including an IMRT technique. Int J Radiat Oncol Biol Phys 2007; 67: 933-941.
28. Munier FL, Verwey J, Pica A, et al. New developments in external beam radiotherapy for retinoblastoma: From lens to normal tissue-sparing techniques. Clin Experiment Ophthalmol 2008; 36: 78-89.
29. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006; 65: 1-7.
30. Krasin MJ, Crawford BT, Zhu Y, et al. Intensity-modulated radiation therapy for children with intraocular retinoblastoma: Potential sparing of the bony orbit. Clin Oncol (R Coll Radiol) 2004; 16: 215-222.
31. Turaka K, Shields CL, Meadows AT, et al. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer 2012; 59: 121-125.
32. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: Is chemotherapy a factor? Ophthalmology 2007; 114: 1378-1383.
33. Yu CL, Tucker MA, Abramson DH, et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009; 101: 581-591.
34. Kim JW, Yau JW, Moshfeghi D, et al. Orbital fibrosis and intraocular recurrence of retinoblastoma following periocular Carboplatin. J Pediatr Ophthalmol Strabismus 2010; 47: e1-e4.
35. Schmack I, Hubbard GB, Kang SJ, et al. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 2006; 142: 310-315.
36. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000; 18: 12-17.
37. Smits C, Swen SJ, Theo Goverts S, et al. Assessment of hearing in very young children receiving carboplatin for retinoblastoma. Eur J Cancer 2006; 42: 492-500.
38. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer 2009; 52: 637-643.
39. Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 2012; 30: 1034-1041.
40. Demirci H, Shields CL, Meadows AT, et al. Long-term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol 2005; 123: 1525-1530.
41. Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: Four-year experience. Arch Ophthalmol 2011; 129: 732-737.
42. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial Chemotherapy for Retinoblastoma: Report No. 1, Control of Retinal Tumors, Subretinal Seeds, and Vitreous Seeds. Arch Ophthalmol 2011; 129: 1399-1406.
43. Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol 2012; 96: 499-502.
44. Vajzovic LM, Murray TG, Aziz-Sultan MA, et al. Supraselective intra-arterial chemotherapy: Evaluation of treatment-related complications in advanced retinoblastoma. Clin Ophthalmol 2011; 5: 171-176.